The DOI matches its Crossref record.
CD44 and EpCAM: Cancer-Initiating Cell Markers
Abstract
Embryonic stem cells are immortal, can self renew, and differentiate into all cells of the body. The adult organism maintains adult stem cells in regenerative organs that can differentiate into all cells of the respective organ. Virchow's hypothesis that cancer may arise from embryonic-like cells has received strong support, as it was demonstrated that tumors contain few cells, known as cancer stem or cancer-initiating cells (CIC), that account for primary and metastatic tumor growth. CIC are mostly defined by expression of CIC-markers that are associated and correlated with the potential of CIC to grow in xenogeneic mice. CIC marker profiles have been elaborated for many tumors, with several markers as CD24, CD44, CD133, CD166, EpCAM, and some integrins, being expressed by tumors of different histological type. Their function in promoting CIC maintenance and activity is largely unknown. The fate of stem cells, determined by their position, is minutely regulated by few adjacent cells creating a niche. CIC also require a niche, mostly for settlement and growth in distant organs. This so called pre-metastatic niche is initiated by the primary tumor before metastasizing cell arrival. How do CIC prepare the pre-metastatic niche? Cancer cells secrete a matrix that serves a cross-talk with surrounding tissues. Additionally, cancer cells can abundantly deliver exosomes, which function as long-distance intercellular communicators. Studies on a rat pancreatic adenocarcinoma support our hypothesis that tumor-derived matrix and exosomes are the main actors in forming the pre-metastatic niche with CIC markers being engaged in matrix preparation and/or exosome delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?
Zöller, M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3023 · Cited by 1,112
Non-Small Cell Lung Cancer Cells Expressing CD44 Are Enriched for Stem Cell-Like Properties
Leung, E. L.-H., Fiscus, R. R., Tung, J. W., Tin, V. P.-C., Cheng, L. C., Sihoe, A. D.-L., Fink, L. M., Ma, Y., & Wong, M. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014062 · Cited by 473
PC3 is a cell line characteristic of prostatic small cell carcinoma
Tai, S., Sun, Y., Squires, J. M., Zhang, H., Oh, W. K., Liang, C., & Huang, J. (2011) · The Prostate · doi:10.1002/pros.21383 · Cited by 438
Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments
Taylor, D. D., & Gercel-Taylor, C. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-010-0234-8 · Cited by 383
CD44v6 Dependence of Premetastatic Niche Preparation by Exosomes
Jung, T., Castellana, D., Klingbeil, P., Hernández, I. C., Vitacolonna, M., Orlicky, D. J., Roffler, S. R., Brodt, P., & Zöller, M. (2009) · Neoplasia · doi:10.1593/neo.09822 · Cited by 345
Self-citation
Metadata
- Authors
- Marhaba, R., Klingbeil, P., Nuebel, T., Nazarenko, I., Buechler, M., & Zoeller, M.
- Venue
- Current Molecular Medicine
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-12-01
- Volume
- 8
- Issue
- 8
- Pages
- 784-804
- ISSN
- 1566-5240 (ISSN-L)
- OpenAlex
- W2143350625
- Cited by
- 192
- References
- 0
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD44 and EpCAM: Cancer-Initiating Cell Markers. https://app.cochat.ai/papers/10.2174/156652408786733667
- The paper
- Marhaba, R., Klingbeil, P., Nuebel, T., Nazarenko, I., Buechler, M., & Zoeller, M. (2008). CD44 and EpCAM: Cancer-Initiating Cell Markers. Current Molecular Medicine. https://doi.org/10.2174/156652408786733667
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.